• Latest Posts

BIO-Europe 2023: top ten highlights

A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy

Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered

M&As: what’s up with the ADC buying spree?

With $700 million Q3 rise, U.K. biotech spearheads European recovery

BioTechX 2023: the highlights